CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

被引：0
|
作者：
Exposito, M. J. Jimenez [1 ]
Akce, M. [2 ]
Montero Alvarez, J. L. [3 ]
Assenat, E. [4 ]
Balart, L. A. [5 ]
Baron, A. D. [6 ]
Decaens, T. [7 ]
Heurgue-Berlot, A. [8 ]
Martin, A. O. [9 ]
Paik, S. W. [10 ]
Poulart, V. [11 ]
Sehbai, A. S. [12 ]
Takemura, N. [13 ]
Yoon, J-H. [14 ]
机构：
[1] Bristol Myers Squibb, Clin Dev Oncol, Princeton, NJ USA
[2] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Hosp Univ Reina Sofia, Gastroenterol, Cordoba, Spain
[4] CHU Montpellier, Med Oncol, Hosp St Eloi, Montpellie, France
[5] Tulane Univ, Internal Med, Tulane Med Ctr, Hlth Sci Ctr, New Orleans, LA 70118 USA
[6] Calif Pacific, Med Ctr, San Francisco, CA USA
[7] CHU Grenoble Alpes, Clin Univ Hepatogastroenterol, Grenoble, France
[8] CHU Reims, Dept Hepatogastroenterol, Reims, France
[9] UAM, Digest Syst Serv, Hosp Univ La Paz, Madrid, Spain
[10] Sungkyunkwan Univ, Samsung Med Ctr, Gastroenterol, Seoul, South Korea
[11] Bristol Myers Squibb, Biostat, Braine Lalleud, Belgium
[12] Pinnacle Res Grp Llc, Hematol Oncol, Anniston, AL USA
[13] Tokyo Natl Ctr Global Hlth & Med, Gastroenterol Surg, Tokyo, Japan
[14] Seoul Natl Univ Hosp, Gastroenterol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
783TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
    Li, Qiu
    Qin, Shukui
    Gu, Shanzhi
    Chen, Xiaoming
    Lin, Lizhu
    Wang, Zishu
    Xu, Aibing
    Chen, Xi
    Zhou, Cuncai
    Ren, Zhenggang
    Yang, Lin
    Xu, Li
    Bai, Yuxian
    Chen, Lei
    Li, Jun
    Pan, Hongming
    Cao, Bangwei
    Fang, Weijia
    Yan, Ping
    Jin, Chunlei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Adjuvant therapy with donafenib plus anti-PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study)
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Study on adjuvant Therapy of Renal Cell Carcinoma after Nephrectomy Randomized, double-blind, placebo-controlled Phase III Study of Pembrolizumab (MK-3475) as adjuvant Monotherapy of Renal Cell Carcinoma after Nephrectomy
    Rexer, H.
    Doehn, C.
    Merseburger, A.
    UROLOGE, 2019, 58 (02): : 225 - 226
  • [34] Adjuvant Photodynamic Therapy Does Not Prevent Recurrence of Condylomata Acuminata After Carbon Dioxide Laser Ablation-A Phase III, Prospective, Randomized, Bicentric, Double-Blind Study
    Szeimies, Rolf-Markus
    Schleyer, Verena
    Moll, Ingrid
    Stocker, Marcus
    Landthaler, Michael
    Karrer, Sigrid
    DERMATOLOGIC SURGERY, 2009, 35 (05) : 757 - 764
  • [35] JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma
    Kobayashi, S.
    Ueshima, K.
    Moriguchi, M.
    Takayama, T.
    Izumi, N.
    Yoshiji, H.
    Hino, K.
    Oikawa, T.
    Chiba, T.
    Motomura, K.
    Kato, J.
    Yasuchika, K.
    Ido, A.
    Kinoshita, J.
    Sato, T.
    Ikeda, M.
    Okusaka, T.
    Kudo, M.
    Tamura, K.
    Furuse, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
    Pal, Sumanta Kumar
    Uzzo, Robert
    Karam, Jose Antonio
    Master, Viraj A.
    Donskov, Frede
    Suarez, Cristina
    Albiges, Laurence
    Rini, Brian
    Tomita, Yoshihiko
    Kann, Ariel Galapo
    Procopio, Giuseppe
    Massari, Francesco
    Zibelman, Matthew
    Antonyan, Igor
    Huseni, Mahrukh
    Basu, Debasmita
    Ci, Bo
    Leung, William
    Khan, Omara
    Dubey, Sarita
    Bex, Axel
    LANCET, 2022, 400 (10358) : 1103 - 1116
  • [37] Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial
    Khene, Zine-Eddine
    Borchiellini, Delphine
    Bensalah, Karim
    EUROPEAN UROLOGY, 2023, 83 (05) : 475 - 476
  • [38] A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
    Rischin, D.
    Fury, M. G.
    Lowy, I.
    Stankevich, E.
    Li, S.
    Han, H.
    Porceddu, S. V.
    ANNALS OF ONCOLOGY, 2019, 30 : 560 - 560
  • [39] Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
    Park, S.
    Sun, J-M
    Choi, Y-L
    Oh, D.
    Kim, H. K.
    Lee, T.
    Chi, S. A.
    Lee, S-H
    Choi, Y. S.
    Jung, S-H
    Ahn, M-J
    Ahn, Y. C.
    Park, K.
    Shim, Y. M.
    ESMO OPEN, 2022, 7 (01)
  • [40] A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
    Rischin, Danny
    Fury, Matthew G.
    Lowy, Israel
    Stankevich, Elizabeth
    Han, Hyunsil
    Porceddu, Sandro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345